LE BARZ, Melanie; ANHE, Fernando F.; VARIN, Thibaut V.; DESJARDINS, Yves; LEVY, Emile; ROY, Denis; URDACI, Maria C.; MARETTE, Andre

doi:10.4093/dmj.2015.39.4.291

Métadonnées

Afficher la notice complète

Licence d’utilisation du document

Langue

Article de revue

Ce document a été publié dans

Diabetes & metabolism journal. 2015, vol. 39, n° 4, p. 291-303

Résumé en anglais

Over the past decade, growing evidence has established the gut microbiota as one of the most important determinants of metabolic disorders such as obesity and type 2 diabetes. Indeed, obesogenic diet can drastically alter bacterial populations (i.e., dysbiosis) leading to activation of pro-inflammatory mechanisms and metabolic endotoxemia, therefore promoting insulin resistance and cardiometabolic disorders. To counteract these deleterious effects, probiotic strains have been developed with the aim of reshaping the microbiome to improve gut health. In this review, we focus on benefits of widely used probiotics describing their potential mechanisms of action, especially their ability to decrease metabolic endotoxemia by restoring the disrupted intestinal mucosal barrier. We also discuss the perspective of using new bacterial strains such as butyrate-producing bacteria and the mucolytic Akkermansia muciniphila, as well as the use of prebiotics to enhance the functionality of probiotics. Finally, this review introduces the notion of genetically engineered bacterial strains specifically developed to deliver anti-inflammatory molecules to the gut.< Réduire

Métadonnées

Partager cette publication !

Licence d’utilisation du document

Probiotics as Complementary Treatment for Metabolic Disorders

Langue

Ce document a été publié dans

Résumé en anglais

URI

DOI

Unités de recherche